Characterization of immune-related adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC Meeting Abstract
| Authors: | Beer, T. M.; Logothetis, C.; Gerritsen, W. R.; Kwon, E. D.; Scher, H. I.; Bossi, A.; Van Den Eertwegh, A. J. M.; Drake, C. G.; McHenry, B.; Liu, D.; Fizazi, K. |
| Abstract Title: | Characterization of immune-related adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC |
| Meeting Title: | 2014 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2014 Jan 30-Feb 1 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-02-01 |
| Language: | English |
| ACCESSION: | WOS:000335318100055 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.4_suppl.52 |
| Notes: | Meeting Abstract: 52 -- Genitourinary Cancers Symposium -- JAN 30-FEB 01, 2014 -- San Francisco, CA -- S -- Source: Wos |
